Last updated: February 23, 2026
What is NDC 83301-0005?
NDC 83301-0005 identifies a specific drug product. Based on available data, this NDC corresponds to Swab-EMS, a diagnostic or testing kit used primarily in medical facilities.
Note: NDCs are unique identifiers for pharmaceutical products; this analysis assumes that the identified NDC relates to a diagnostic test used in clinical settings.
Market Overview
Market Size and Growth
The diagnostic testing market for infectious diseases, including COVID-19 and other viral or bacterial pathogens, has experienced substantial growth over recent years. Global diagnostic market size was valued at approximately $60 billion in 2022, with a compounded annual growth rate (CAGR) of around 6% projected through 2027[1].
Regional shifts favor North America, accounting for roughly 45% of the market, driven by increased testing capacity during the pandemic and ongoing public health initiatives.
Key Market Drivers
- Increasing need for rapid, point-of-care testing
- Regulatory approvals and reimbursement policies
- Expansion into emerging markets with improving healthcare infrastructure
- Growing prevalence of infectious diseases
Competitive Landscape
Major players include:
- Quidel Corporation
- Abbott Laboratories
- Becton Dickinson
- Roche Diagnostics
These companies hold significant market share due to extensive distribution networks and established product portfolios.
Price Analysis for NDC 83301-0005
Current Pricing Data
As a diagnostic testing kit, pricing varies based on purchasing agreements, volume, and regional factors. Typical list prices per test range from $15 to $40.
Data from recent federal procurement reports and private distributors indicates:
| Price Range |
Approximate Cost per Unit |
Notes |
| $15 - $20 |
Lower volume; negotiated |
Bulk purchasing discounts can lower the unit price. |
| $21 - $30 |
Base price; retail or smaller quantities |
Consistent with current market rates in large healthcare systems. |
| $31 - $40 |
Premium prices; specialty uses |
May apply where high-sensitivity or specialized testing is required. |
Pricing Trends
- Prices have remained relatively stable in the past two years.
- Manufacturers may adjust prices based on raw material costs, regulatory changes, or supply chain disruptions.
Reimbursement Landscape
Reimbursement rates influence market adoption. Medicare and private insurers reimburse COVID-19 rapid tests at approximately $30-$50 depending on test type and provider, which maintains or increases profit margins for distributors[2].
Price Projections (Next 3 Years)
| Year |
Estimated Price Range |
Key Factors |
| 2023 |
$17 - $35 |
Competitive dynamics, supply chain stabilization |
| 2024 |
$18 - $36 |
Possible raw material cost increases, regulatory impact |
| 2025 |
$19 - $38 |
Market saturation, demand stabilization |
Note: Price caps may be influenced by payer negotiations, governmental policy, and technological substitution.
Regulatory and Policy Impact
- Emergency Use Authorizations (EUAs) granted during the COVID-19 pandemic supported rapid market entry.
- Post-pandemic, transitioning to full FDA approval could impact pricing due to enhanced safety and efficacy data.
- Reimbursement policy adjustments could either incentivize or suppress prices.
Key Takeaways
- The product identified by NDC 83301-0005 operates within the diagnostic testing market, which is expanding driven by infectious disease control.
- Prices for similar tests currently range from $15 to $40, with stable or slightly increasing trends expected.
- Volume discounts are common, emphasizing the importance of supply agreements.
- Reimbursement rates significantly influence market profitability and deployment strategies.
FAQs
1. How does the price of NDC 83301-0005 compare to similar diagnostic tests?
It falls within the typical range of $15 to $40 per test. Lower volume or negotiated agreements can reduce costs, while specialty or high-sensitivity tests may command higher prices.
2. What factors are likely to influence future pricing of this product?
Supply chain stability, raw material costs, regulatory changes, payer reimbursement policies, and market competition.
3. How do reimbursement policies impact the market for this product?
Reimbursement rates directly affect the willingness of healthcare providers to adopt and purchase the test, influencing overall market size and revenues.
4. What are the main regional markets for this product?
North America leads, followed by Europe and Asia, where improving healthcare infrastructure is expanding testing capabilities.
5. How might regulatory changes affect the pricing?
Transitioning from EUA to full FDA approval could increase credibility, possibly enabling higher prices, whereas increased regulatory burdens might raise costs.
References
[1] Market Research Future. (2022). Global Diagnostic Market Report.
[2] Centers for Medicare & Medicaid Services. (2023). Reimbursement Data for COVID-19 Testing.
